LumaBridge promotes Todd Lehman to CEO fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
The Persistent Corneal Epithelial Defects pipeline therapies expected to get launched in the forecasted period include Nexagon, ST266, RGN-259, REC-0559, and others. These are expected to create
/PRNewswire/ DelveInsight s Persistent Corneal Epithelial Defects (PEDs or PCEDs) Market report offers detailed information on current treatment practices,.
/PRNewswire/ DelveInsight s Persistent Corneal Epithelial Defects (PEDs or PCEDs) Market report offers detailed information on current treatment practices,.
(Sanofi)
French Big Pharma Sanofi is teaming up with Germany’s Sirion Biotech for its viral-vector-based gene delivery tech.
The pair will work together on developing improved tissue-selective adeno-associated virus (AAV) vectors to tee up better gene therapy treatments. Targets have not yet been specifically mentioned, simply for “disorders affecting major human organs.” Financials of the deal were not made public.
This comes two years after Sirion penned a similar pact with Denali Therapeutics, with other partners including Acucela and Orchard Therapeutics.
Sanofi will work with Sirion and the German company’s partner at Heidelberg University Hospital, Dirk Grimm, to develop new and modified AAV capsids. The overall goal is to make safer, better gene therapies.